{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T23:45:54Z","timestamp":1773877554301,"version":"3.50.1"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014337","name":"A Menarini Pharmaceutical Industries Riunite","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ijid.2025.108165","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T22:42:26Z","timestamp":1762209746000},"page":"108165","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["In vitro characterization of delafloxacin activity against intracellular Legionella: Exploring new treatment options for Legionnaires\u2019 disease"],"prefix":"10.1016","volume":"162","author":[{"given":"Roger","family":"Cort\u00e8s-Tarrag\u00f3","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisenda","family":"Arqu\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lluc","family":"Vinyeta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Basart Altieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarahi Marieliza","family":"Elizondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nieves","family":"Sopena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esteban","family":"Reynaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"D\u00edez de los R\u00edos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Quero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0376-5036","authenticated-orcid":false,"given":"Noem\u00ed","family":"P\u00e1rraga-Ni\u00f1o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luisa","family":"Pedro-Botet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2025.108165_bib0001","unstructured":"European Center for Disease Prevention and Control. Surveillance. Atlas of Infectious Diseases, https:\/\/atlas.ecdc.europa.eu\/public\/index.aspx?Dataset=27&HealthTopic=30; n.d. [accessed 12 February 2025]."},{"key":"10.1016\/j.ijid.2025.108165_bib0002","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1128\/aem.41.1.9-16.1981","article-title":"Ecological distribution of Legionella pneumophila","volume":"41","author":"Fliermans","year":"1981","journal-title":"Appl Environ Microbiol"},{"key":"10.1016\/j.ijid.2025.108165_bib0003","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1128\/aem.37.6.1239-1242.1979","article-title":"Isolation of Legionella pneumophila from nonepidemic-related aquatic habitats","volume":"37","author":"Fliermans","year":"1979","journal-title":"Appl Environ Microbiol"},{"key":"10.1016\/j.ijid.2025.108165_bib0004","series-title":"Legionella and the prevention of legionellosis","year":"2007"},{"key":"10.1016\/j.ijid.2025.108165_bib0005","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1146\/annurev-pathmechdis-012419-032742","article-title":"Legionnaires\u2019 disease: state of the art knowledge of pathogenesis mechanisms of Legionella","volume":"15","author":"Mondino","year":"2020","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.ijid.2025.108165_bib0006","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1128\/aem.57.2.597-600.1991","article-title":"Detection of viable Legionella pneumophila in water by polymerase chain reaction and gene probe methods","volume":"57","author":"Bej","year":"1991","journal-title":"Appl Environ Microbiol"},{"key":"10.1016\/j.ijid.2025.108165_bib0007","doi-asserted-by":"crossref","first-page":"5088","DOI":"10.1128\/AEM.02932-09","article-title":"Specific and rapid enumeration of viable but nonculturable and viable-culturable gram-negative bacteria by using flow cytometry","volume":"76","author":"Khan","year":"2010","journal-title":"Appl Environ Microbiol"},{"key":"10.1016\/j.ijid.2025.108165_bib0008","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jhin.2017.09.006","article-title":"Detection of viable but non-culturable legionella in hospital water network following monochloramine disinfection","volume":"98","author":"Casini","year":"2018","journal-title":"J Hosp Infect"},{"key":"10.1016\/j.ijid.2025.108165_bib0009","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.diagmicrobio.2016.04.009","article-title":"A multicenter study of viable PCR using propidium monoazide to detect Legionella in water samples","volume":"85","author":"Scaturro","year":"2016","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijid.2025.108165_bib0010","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/j.1574-6976.2009.00200.x","article-title":"Recent findings on the viable but nonculturable state in pathogenic bacteria","volume":"34","author":"Oliver","year":"2010","journal-title":"FEMS Microbiol Rev"},{"key":"10.1016\/j.ijid.2025.108165_bib0011","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/s40121-022-00635-7","article-title":"Legionnaires\u2019 disease: update on diagnosis and treatment","volume":"11","author":"Viasus","year":"2022","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.ijid.2025.108165_bib0012","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13613-024-01252-y","article-title":"Severe Legionnaires\u2019 disease","volume":"14","author":"Rello","year":"2024","journal-title":"Ann Intensive Care"},{"key":"10.1016\/j.ijid.2025.108165_bib0013","doi-asserted-by":"crossref","first-page":"9352","DOI":"10.3390\/ijerph18179352","article-title":"Antibiotic susceptibility of environmental Legionella pneumophila Strains isolated in Northern Italy","volume":"18","author":"Cocuzza","year":"2021","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.ijid.2025.108165_bib0014","article-title":"Antimicrobial susceptibility profiles and tentative epidemiological cutoff values of Legionella pneumophila from environmental water and soil sources in China","volume":"13","author":"Yang","year":"2022","journal-title":"Front Microbiol"},{"key":"10.1016\/j.ijid.2025.108165_bib0015","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1093\/jac\/dkac173","article-title":"Detection of highly macrolide-resistant Legionella pneumophila strains from a hotel water network using systematic whole-genome sequencing","volume":"77","author":"Ginevra","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2025.108165_bib0016","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.ebiom.2015.07.018","article-title":"Hidden selection of bacterial resistance to fluoroquinolones in vivo: the case of Legionella pneumophila and humans","volume":"2","author":"Shadoud","year":"2015","journal-title":"EBiomedicine"},{"key":"10.1016\/j.ijid.2025.108165_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijid.2025.107786","article-title":"Occurrence of macrolides resistance in Legionella pneumophila ST188: results of the Belgian epidemiology and resistome investigation of clinical isolates","volume":"153","author":"Michel","year":"2025","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ijid.2025.108165_bib0018","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1093\/jac\/dkp173","article-title":"Mutational paths towards increased fluoroquinolone resistance in Legionella pneumophila","volume":"64","author":"Almahmoud","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2025.108165_bib0019","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02188-16","article-title":"Ribosomal mutations conferring macrolide resistance in Legionella pneumophila","volume":"61","author":"Descours","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2025.108165_bib0020","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1086\/428059","article-title":"Clinical outcomes for hospitalized patients with Legionella pneumonia in the antigenuria era: the influence of levofloxacin therapy","volume":"40","author":"Mykietiuk","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2025.108165_bib0021","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1378\/chest.128.3.1401","article-title":"Fluoroquinolones vs macrolides in the treatment of Legionnaires disease","volume":"128","author":"Sabri\u00e0","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.ijid.2025.108165_bib0022","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1164\/rccm.201908-1581ST","article-title":"Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America","volume":"200","author":"Metlay","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ijid.2025.108165_bib0023","series-title":"Critically important antimicrobials for human medicine. 3rd rev","year":"2012"},{"key":"10.1016\/j.ijid.2025.108165_bib0024","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12941-016-0150-4","article-title":"Chemical structure and pharmacokinetics of novel quinolone agents represented by avarofloxacin, delafloxacin, finafloxacin, zabofloxacin and nemonoxacin","volume":"15","author":"Kocsis","year":"2016","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"10.1016\/j.ijid.2025.108165_bib0025","doi-asserted-by":"crossref","first-page":"S223","DOI":"10.1093\/cid\/ciz006","article-title":"Analysis of pooled Phase III efficacy data for delafloxacin in acute bacterial skin and skin structure infections","volume":"68","author":"Giordano","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2025.108165_bib0026","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofae631.1670","article-title":"P-1501. Intracellular activity of delafloxacin against small colony variant Staphylococcus aureus","volume":"12","author":"Tudahl","year":"2025","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijid.2025.108165_bib0027","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1128\/AAC.01201-10","article-title":"Contrasting effects of acidic pH on the extracellular and intracellular activities of the anti-gram-positive fluoroquinolones moxifloxacin and delafloxacin against Staphylococcus aureus","volume":"55","author":"Lemaire","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2025.108165_bib0028","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.3390\/pharmaceutics13081289","article-title":"Structural characterization of the millennial antibacterial (fluoro)quinolones-shaping the fifth generation","volume":"13","author":"Rusu","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijid.2025.108165_bib0029","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1128\/AAC.47.10.3260-3269.2003","article-title":"In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone","volume":"47","author":"Nilius","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2025.108165_bib0030","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s40121-018-0198-x","article-title":"Delafloxacin: place in therapy and review of microbiologic, clinical and pharmacologic properties","volume":"7","author":"Jorgensen","year":"2018","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.ijid.2025.108165_bib0031","doi-asserted-by":"crossref","first-page":"3469","DOI":"10.1128\/AAC.04813-14","article-title":"A thorough QT study to evaluate the effects of therapeutic and supratherapeutic doses of delafloxacin on cardiac repolarization","volume":"59","author":"Litwin","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2025.108165_bib0032","doi-asserted-by":"crossref","first-page":"ofy220","DOI":"10.1093\/ofid\/ofy220","article-title":"Safety of delafloxacin: focus on adverse events of special interest","volume":"5","author":"Lodise","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijid.2025.108165_bib0033","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/cid\/ciy165","article-title":"A comparison of the efficacy and safety of intravenous followed by oral delafloxacin with vancomycin plus aztreonam for the treatment of acute bacterial skin and skin structure infections: a phase 3, multinational, double-blind, randomized study","volume":"67","author":"O\u2019Riordan","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2025.108165_bib0034","doi-asserted-by":"crossref","first-page":"3471","DOI":"10.1093\/jac\/dkx329","article-title":"Efficacy and safety of delafloxacin compared with vancomycin plus aztreonam for acute bacterial skin and skin structure infections: a phase 3, double-blind, randomized study","volume":"72","author":"Pullman","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2025.108165_bib0035","first-page":"ofz514","article-title":"A Phase 3 study to compare delafloxacin with moxifloxacin for the treatment of adults with community-acquired bacterial pneumonia (DEFINE-CABP)","volume":"7","author":"Horcajada","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijid.2025.108165_bib0036","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ijid.2020.06.018","article-title":"Efficacy of delafloxacin versus moxifloxacin against atypical bacterial respiratory pathogens in adults with community-acquired bacterial pneumonia (CABP): data from the delafloxacin Phase 3 CABP Trial","volume":"97","author":"McCurdy","year":"2020","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ijid.2025.108165_bib0037","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/j.ijheh.2017.08.007","article-title":"Viability qPCR, a new tool for Legionella risk management","volume":"220","author":"Lizana","year":"2017","journal-title":"Int J Hyg Environ Health"},{"key":"10.1016\/j.ijid.2025.108165_bib0038","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1007\/s40265-020-01358-0","article-title":"Delafloxacin: a review in acute bacterial skin and skin structure infections","volume":"80","author":"Scott","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.ijid.2025.108165_bib0039","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1517\/14656560902900820","article-title":"Treatment strategies for Legionella infection","volume":"10","author":"Pedro-Botet","year":"2009","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.ijid.2025.108165_bib0040","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ejim.2023.09.013","article-title":"Legionella pneumonia in hospitalized adults with respiratory failure: quinolones or macrolides?","volume":"120","author":"Ruiz-Spinelli","year":"2024","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.ijid.2025.108165_bib0041","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.jiac.2018.01.018","article-title":"In vitro activity of various antibiotics against clinical strains of Legionella species isolated in Japan","volume":"24","author":"Miyashita","year":"2018","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.ijid.2025.108165_bib0042","doi-asserted-by":"crossref","DOI":"10.1016\/j.mimet.2024.107071","article-title":"Broth microdilution protocol for determining antimicrobial susceptibility of Legionella pneumophila to clinically relevant antimicrobials","volume":"228","author":"Sewell","year":"2025","journal-title":"J Microbiol Methods"},{"key":"10.1016\/j.ijid.2025.108165_bib0043","series-title":"The European committee on antimicrobial susceptibility testing (EUCAST)","year":"2021"},{"key":"10.1016\/j.ijid.2025.108165_bib0044","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1007\/s10096-024-04789-9","article-title":"Antimicrobial susceptibility testing reveals reduced susceptibility to azithromycin and other antibiotics in Legionella pneumophila serogroup 1 isolates from Portugal","volume":"43","author":"Minetti","year":"2024","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijid.2025.108165_bib0045","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ijantimicag.2011.05.001","article-title":"Rifampicin\u2013macrolide synergy against Legionella pneumophila serogroup 1 in human macrophages using a quantitative real-time PCR assay","volume":"38","author":"Descours","year":"2011","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijid.2025.108165_bib0046","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1078\/1438-4221-00140","article-title":"A point mutation in the active site of Legionella pneumophila O-acetyltransferase results in modified lipopolysaccharide but does not influence virulence","volume":"291","author":"L\u00fcck","year":"2001","journal-title":"Int J Med Microbiol"},{"key":"10.1016\/j.ijid.2025.108165_bib0047","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241914602","article-title":"Lipopolysaccharide of Legionella pneumophila serogroup 1 facilitates interaction with host cells","volume":"24","author":"Kowalczyk","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ijid.2025.108165_bib0048","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.colsurfb.2010.08.040","article-title":"Impact of the virulence-associated MAb3\/1 epitope on the physicochemical surface properties of Legionella pneumophila sg1: an issue to explain infection potential?","volume":"82","author":"Gosselin","year":"2011","journal-title":"Colloids Surf B Biointerfaces"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S120197122500387X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S120197122500387X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T16:47:14Z","timestamp":1773852434000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S120197122500387X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":48,"alternative-id":["S120197122500387X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2025.108165","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro characterization of delafloxacin activity against intracellular Legionella: Exploring new treatment options for Legionnaires\u2019 disease","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2025.108165","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}],"article-number":"108165"}}